The ACUF applauds the U.S. Senate for its unanimous consent on Thursday of the Trickett Wendler Right-to-Try bill

The American Conservative Union Foundation (ACUF) applauds the United States Senate for its unanimous consent on Thursday of the Trickett Wendler Right-to-Try bill. The legislation, which has already received support from the White House, would remove unnecessary barriers standing in the way of delivering hope and treatment to terminally ill individuals by granting them the right to access investigative therapies that may save their lives. Patients who have run out of treatment options would, under this law, be free to try drugs and devices that are in clinical trials but not yet approved. Similar laws have already been passed by 37 states and have documented success stories of pairing patients with life-saving treatments.
“This enables patients to continue to pursue life and liberty, even as they face the harshest realities that come with terminal and life-threatening diagnoses,” said Jackie Anderson, Director of Policy and Public Affairs at the ACUF. “Where once a terminally ill patient and her family had to cling to the prospects of winning a lottery to get into a clinical trial, this law would allow them the same opportunity at treatment – at life – as those lucky enough to be chosen.”

The Right-to-Try bill now heads to the House of Representatives, where the ACU hopes it will pass swiftly so that no more Americans are denied the right to try to save their own life.


Policy Center Switcher


ACU Ratings

The ACU tracks a wide range of issues before Congress to determine which issues and votes serve as a dividing line to help those members of U.S. House and Senate who protect liberty as a conservative and those who are truly liberal. CLICK HERE FOR RATINGS
The ACU Foundation seeks to educate the next generation of conservative leaders by providing them the intellectual tools necessary to learn about the conservative movement, its leaders, its leading organization and especially its principles.

1331 H St NW Suite 500
Washington, DC 20005
Ph: (202) 347-9388 | Fx: (202) 347-9389